Attivare Therapeutics to Present Preclinical Data for ATT-01 and ATT-02 at the American Association for Cancer Research (AACR) Annual Meeting 2025 NATICK, Mass.--(BUSINESS WIRE)--Attivare Therapeutics, an innovative oncology company, will present preclinical data for its ATT-01 and ATT-02 cancer therapies at the American Association for Cancer Research (AACR) Annual Meeting 2025. These presentations highlight the capabilities of the company's ATTimmune platform, which uses a biomaterial scaffold to create a new physical microenvironment within the body, attracting and activating immune cells to combat solid and liquid tumors. ATT-01: Inducing Differentiation and Durable Remission ATT-01 leverages the ATTimmune platform, specifically a silica-based, biodegradable scaffold known as mesoporous silica rods (MSR). This scaffold is loaded with GM-CSF and CpG, which together induce the differentiation of acute myeloid leukemia (AML) blasts in vitro. Furthermore, ATT-01 elicits a significant vaccine-like T-cell response and achieves durable remission in syngeneic murine models of AML. ATT-02: Potent Anti-Tumor Immunity with IL-12 ATT-02 combines the ATTimmune scaffold with Interleukin 12 (IL-12) to enhance anti-tumor immunity. When administered intratumorally, ATT-02 demonstrates superior effectiveness compared to IL-12 alone in multiple single and abscopal tumor syngeneic models. Notably, complete responses were observed in two colon carcinoma models after a single dose of ATT-02. ATTimmune alone also showed anti-tumor activity by delaying tumor progression and repolarizing macrophages to an immunogenic phenotype that drives T-cell activation. The addition of IL-12 further amplifies this effect, making ATT-02 a promising candidate for cancer therapy. Advantages of the ATTimmune Platform David Sherris, President and CEO of Attivare Therapeutics, expressed enthusiasm about the upcoming presentation. "We are delighted to showcase our preclinical data for ATT-01 and ATT-02 at the AACR Annual Meeting. The ATTimmune platform represents a novel silica-based approach to delivering strong immune agonists to fight cancer. One of its key advantages is its ability to bind a wide range of therapeutic agents, from biologics and small molecules to gene therapy and cellular technologies, without altering their properties. The platform ensures controlled release of the drugs over a 21-day period, and due to its size, it stays localized at the injection site, which is crucial for maintaining efficacy within the tumor microenvironment. This localization also helps reduce or eliminate systemic toxicity, a common issue with many cancer treatments." Details of the Poster Presentations The two poster presentations at AACR 2025 will cover the following topics: Title: Delivery of CpG and GM-CSF in a Novel Silica-Based Scaffold Leads to Differentiation of AML Blasts and T Cell-Dependent Immunity in Syngeneic AML Tumor Models - This poster will detail how ATT-01’s silica-based scaffold delivers GM-CSF and CpG to effectively differentiate AML blasts and generate a robust T-cell immune response, leading to long-lasting remission in murine models. Title: A Single Intratumoral Injection of IL-12 Bound to Mesoporous Silica Rods Generates Effective Anti-Tumor Immune Responses and Tumor Growth Control in Multiple Syngeneic Tumor Models - This presentation will highlight the potency of ATT-02 in generating anti-tumor immune responses and controlling tumor growth in various syngeneic models, emphasizing the synergistic effects of combining the scaffold with IL-12. About Attivare Therapeutics, Inc. Attivare Therapeutics was established by a dedicated team from the Wyss Institute at Harvard. The company's primary focus is on addressing the challenge of treating low-immunogenic tumors through the development of its ATTimmune platform. This cutting-edge technology uses proprietary biomaterial scaffolds to recruit, reprogram, and release targeted immune cells, offering unprecedented three-dimensional spatiotemporal control of bioactive components. By customizing the scaffolds with different immunomodulators, the platform can effectively reprogram the immune environment to enhance patient immune responses. The ATTimmune platform is designed to integrate seamlessly with standard care practices and has potential applications in areas beyond oncology, such as infectious diseases. For more information on Attivare Therapeutics, visit their website or follow their latest news updates.